Supplementary Figure 1. An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma.

This study was funded and supported by EMulate Therapeutics, Inc. (formerly known as Nativis, Inc.). S Kesari was previously an advisor for Emulate Therapeutics, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.